MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) (NCT06128629)
MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
🩺 Plain-English Summary (8th-Grade Level)
To evaluate the efficacy and safety of a single dose of NTLA-2001 compared to placebo in participants with ATTR-CM.
Who can join: Review the eligibility criteria below.
Location: University of Arizona — Tucson, Arizona
Age range: 18 Years to 90 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (132 Sites)
Showing the first 25 of 132 sites.
- University of Arizona — Tucson, Arizona
- Cedars-Sinai Medical Center — Los Angeles, California
- Western Greater Los Angeles VA Medical Center — Los Angeles, California
- Stanford University — Palo Alto, California
- University of California, San Diego (UCSD) - Medical Center — San Diego, California
- University of Colorado Denver — Denver, Colorado
- Yale University School of Medicine — New Haven, Connecticut
- MedStar Washington Hospital Center - MedStar Heart and Vascular Institute — Washington D.C., District of Columbia
- Mayo Clinic - Jacksonville — Jacksonville, Florida
- Cleveland Clinic of Florida — Weston, Florida
- Emory University School of Medicine — Atlanta, Georgia
- Northwestern University — Chicago, Illinois
- Indiana University Health — Indianapolis, Indiana
- University of Kentucky Gill Heart Institute — Lexington, Kentucky
- Johns Hopkins University — Baltimore, Maryland
- Brigham and Women's Hospital — Boston, Massachusetts
- Boston University School of Medicine — Boston, Massachusetts
- University of Michigan — Ann Arbor, Michigan
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan
- Mayo Clinic — Rochester, Minnesota
- St. Luke's Hospital — Kansas City, Missouri
- New York University (NYU) School of Medicine - Langone Medical Center — New York, New York
- Columbia University Medical Center — New York, New York
- Duke University Medical Center — Durham, North Carolina
- Cleveland Clinic — Cleveland, Ohio
📞 Contact the Study Coordinator
Phone: (857) 285-6200
Email: medicalinformation@intelliatx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Explore by condition: All Transthyretin Amyloidosis (ATTR) With Cardiomyopathy clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.